Stock analysts at Aegis started coverage on shares of CombiMatrix Corp. (NASDAQ:CBMX) in a note issued to investors on Thursday. The firm set a “buy” rating and a $5.00 price target on the stock. Aegis’ price target would suggest a potential upside of 66.67% from the company’s previous close.

CombiMatrix Corp. (NASDAQ:CBMX) opened at 3.00 on Thursday. CombiMatrix Corp. has a 12-month low of $2.62 and a 12-month high of $18.15. The stock’s 50 day moving average is $3.01 and its 200 day moving average is $3.21. The stock’s market capitalization is $7.13 million.

CombiMatrix Corp. (NASDAQ:CBMX) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.62. CombiMatrix Corp. had a negative net margin of 52.71% and a negative return on equity of 80.98%. Equities analysts predict that CombiMatrix Corp. will post ($2.70) earnings per share for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About CombiMatrix Corp.

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.

5 Day Chart for NASDAQ:CBMX

Receive News & Ratings for CombiMatrix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corp. and related companies with's FREE daily email newsletter.